Invenux Inc Profile last edited on: 4/24/18
CAGE: 5N7X4
UEI:
Business Identifier: Orphan disease drugs 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 04
County: Weld
Congr. District: 04
County: Weld
Public Profile
Invenux, LLC is a privately held clinical stage biopharmaceutical company focused on research and development of drugs for orphan diseases. The firm's first drug candidate is SCD-101 for the treatment of sickle cell disease. The primary goal of Invenux is to commercialize orphan drugs like SCD-101 through corporatepartnerships that result in upfront, milestone and royalty payments or the outright sale of Inventux' rights to a pharmaceutical company
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2017 | 2 | NIH | $1,941,809 | |
| Project Title: First Clinical Trial of an Anti-Sickling Botanical Drug for Sickle Cell Dise | ||||
| 2017 | 1 | NIH | $224,731 | |
| Project Title: Identification of the Antisickling Compounds in SCD-101 | ||||
| 2017 | 1 | NIH | $224,950 | |
| Project Title: Crossover Study of an Oral Treatment for Sickle Cell Disease | ||||
| 2013 | 1 | NIH | $397,926 | |
| Project Title: Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity | ||||
| 2002 | 1 | NIH | $99,995 | |
| Project Title: New Anti-HIV Agents from Evolutionary Chemistry | ||||
Key People / Management
Bruce Eaton -- Former President and Founder
Lawrence Melvin -- President
Daniel T Nieuwlandt
Robert Swift
Theodore M Tarasow -- Founder, CSO & VP Chemistry
Lawrence Melvin -- President
Daniel T Nieuwlandt
Robert Swift
Theodore M Tarasow -- Founder, CSO & VP Chemistry
